Abstract: Systemic administration of intact, bacterially derived minicells results in rapid accumulation of the minicells in the microenvironment of a brain tumor, in therapeutically significant concentrations, without requiring endothelial endocytosis/transcytosis across the blood brain barrier or any other mechanism by which, pursuant to conventional approaches, nanoparticles have entered into that microenvironment. Accordingly, a wide variety of brain tumors, both primary and metastatic, can be treated by administering systemically a therapeutically effective amount of a composition comprised of a plurality of such minicells, each minicell being a vehicle for an active agent against the tumor, such as a radionuclide, a functional nucleic acid or a plasmid encoding one, or a chemotherapeutic agent.
Type:
Grant
Filed:
March 25, 2021
Date of Patent:
April 23, 2024
Assignee:
EnGenelC Molecular Delivery Pty Ltd
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: Compositions and methods for treating cancer are provided. In particular, the compositions comprise an anti-neoplastic agent and either an interferon type I agonist or an interferon type II agonist, or a combination of an interferon type I agonist and an interferon type II agonist.
Type:
Grant
Filed:
July 22, 2019
Date of Patent:
November 22, 2022
Assignee:
EnGenelC Molecular Delivery Pty Ltd
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: Compositions and methods for treating cancer are provided. In particular, the compositions comprise an encapsulated CD1d-restricted invariant Natural Killer T (iNKT) cell antigen, such as glycosphingolipid, for example, ?-galactosylceramide. Methods of administering the compositions in combination with a therapy that induces the death of neoplastic cells in the subject are provided.
Type:
Application
Filed:
January 6, 2020
Publication date:
April 7, 2022
Applicant:
EnGenelC Molecular Delivery Pty Ltd
Inventors:
Himanshu BRAHMBHATT, Jennifer MacDiarmid
Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
Type:
Grant
Filed:
May 24, 2017
Date of Patent:
October 15, 2019
Assignee:
EnGenelC Molecular Delivery Pty Ltd
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid, Toby Hulf
Abstract: A method of targeting bacterially-derived, intact minicells to specific, non-phagocytic mammalian cells employs bispecific ligands to deliver nucleic acids efficiently to the mammalian cells. Bispecific ligands, comprising (i) a first arm that carries specificity for a bacterially-derived minicell surface structure and (ii) a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor are useful for targeting minicells to specific, non-phagocytic mammalian cells and causing endocytosis of minicells by non-phagocytic cells.
Type:
Application
Filed:
June 4, 2018
Publication date:
December 27, 2018
Applicant:
EnGenelC Molecular Delivery Pty Ltd.
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells. Another drug delivery method exploits the natural ability of phagocytic mammalian cells to engulf minicells without the use of bispecific ligands.
Type:
Application
Filed:
June 5, 2018
Publication date:
October 4, 2018
Applicant:
EnGenelC Molecular Delivery Pty Ltd
Inventors:
Himanshu BRAHMBHATT, Jennifer MacDiarmid
Abstract: This disclosure provides intact bacterially derived minicells containing nucleic acids adjuvants or plasmids encoding nucleic acids adjuvants that can produce a desired immune response in target cells. This disclosure further provides methods that employ minicells to deliver nucleic acids adjuvants for use in the treatment of diseases, including neoplastic disease and cancer.
Type:
Application
Filed:
October 4, 2017
Publication date:
April 12, 2018
Applicant:
EnGenelC Molecular Delivery Pty. Ltd.
Inventors:
Himanshu BRAHMBHATT, Jennifer MacDiarmid
Abstract: Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter alia, can be combined with chemotherapy to increase the effectiveness of the chemotherapy.
Type:
Application
Filed:
December 29, 2015
Publication date:
April 28, 2016
Applicant:
EnGenelC Molecular Delivery Pty. Ltd.
Inventors:
HIMANSHU BRAHMBHATT, JENNIFER MACDIARMIID
Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.
Type:
Application
Filed:
June 19, 2015
Publication date:
February 25, 2016
Applicant:
EnGenelC Molecular Delivery Pty Ltd
Inventors:
Himanshu BRAHMBHATT, Jennifer MacDiarmid, Toby Hulf
Abstract: A method of targeting bacterially-derived, intact minicells to specific, non-phagocytic mammalian cells employs bispecific ligands to deliver nucleic acids efficiently to the mammalian cells. Bispecific ligands, comprising (i) a first arm that carries specificity for a bacterially-derived minicell surface structure and (ii) a second arm that carries specificity for a non-phagocytic mammalian cell surface receptor are useful for targeting minicells to specific, non-phagocytic mammalian cells and causing endocytosis of minicells by non-phagocytic cells.
Type:
Application
Filed:
August 6, 2015
Publication date:
December 3, 2015
Applicant:
EnGenelC Molecular Delivery Pty Ltd.
Inventors:
Himanshu BRAHMBHATT, Jennifer MacDiarmid
Abstract: Compositions and methods are provided for cancer treatments. The methodology entails, for instance, administering to a cancer patient a first composition comprising a plurality of bacterially derived intact minicells or intact killed bacterial cells, each of which encompasses an anti-neoplastic agent and carries a bispecific ligand on the surface, the ligand having specificity for a mammalian cell component, and a second composition comprising interferon-gamma (IFN-gamma) or an agent that increases the expression of IFN-gamma in the subject. The compositions include the first composition and the second composition as described, optionally with additional anti-neoplastic agents.
Type:
Application
Filed:
October 3, 2014
Publication date:
April 9, 2015
Applicant:
EnGenelC Molecular Delivery Pty Ltd
Inventors:
Himanshu BRAHMBHATT, Jennifer MACDIARMID
Abstract: Systemic administration of intact, bacterially derived minicells results in rapid accumulation of the minicells in the microenvironment of a brain tumor, in therapeutically significant concentrations, without requiring endothelial endocytosis/transcytosis across the blood brain barrier or any other mechanism by which, pursuant to conventional approaches, nanoparticles have entered into that microenvironment. Accordingly, a wide variety of brain tumors, both primary and metastatic, can be treated by administering systemically a therapeutically effective amount of a composition comprised of a plurality of such minicells, each minicell being a vehicle for an active agent against the tumor, such as a radionuclide, a functional nucleic acid or a plasmid encoding one, or a chemotherapeutic agent.